Home
Nykode Therapeutics

Nykode Therapeutics Market Share Analysis for August 2026

The Nykode Therapeutics platform is built around the Vaccibody molecule: An immunotherapy platform for the future of medicine.

Industry: N/A

Domainnykode.com

Year Founded2007

Employees51 - 200

Annual Revenue$10M - $15M

Nykode Therapeutics

Nykode Therapeutics (including company regionals)

nykode.com

See more website traffic and engagement information

Nykode Therapeutics Revenue up to August 2026 is 10M - 15M

revenue generated by Nykode Therapeutics top domains

Nykode Therapeutics top domains revenue over 3 years

Revenue for Nykode Therapeutics top domains

nykode.com10M - 15M

See more with Sales Intelligence

Total visits to Nykode Therapeutics's top domains

Understand Nykode Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

nykode.com314

See more with Sales Intelligence

Avg. visit duration in Nykode Therapeutics's top domains

Analyze Nykode Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

nykode.com--

See more with Sales Intelligence

Avg. pageviews on Nykode Therapeutics's top domains

See how Nykode Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

nykode.com1.01

See more with Sales Intelligence

Nykode Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Nykode Therapeutics

These are the website technologies, by industry, used by Nykode Therapeutics top domains

Mobile (3)

Meta Viewport

Widget (3)

Twemoji

Audio Video Media (1)

Vimeo

Content Management System (1)

WordPress

More Technologies

6

See all

News & Signals from Nykode Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNykode Therapeutics AS received financing of $30.7M on Aug 27th '26.On 27 August 2026, Nykode Therapeutics ASA ("Nykode") announced the successful completion of a private placement, raising gross proceeds of NOK 286 million through the allocation of 65 million new shares at a subscription price of NOK 4.40 per share.

NewsNykode Therapeutics AS attended event Neoantigen Summit on Aug 4th '26.Nykode Therapeutics has presented comprehensive preclinical and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated platform ready for strategic partnership.

NewsNykode Therapeutics AS hires Barbara Krebs-Pohl as chair and approves board remuneration.Nykode Therapeutics appoints Barbara Krebs-Pohl as chair and approves board remuneration.